Dianthus Therapeutics (NASDAQ:DNTH) CFO Sells $700,000.00 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Dianthus Therapeutics Trading Down 1.8%

Shares of DNTH opened at $37.16 on Friday. The business’s 50-day moving average price is $23.01 and its 200 day moving average price is $20.53. The stock has a market capitalization of $1.20 billion, a P/E ratio of -11.43 and a beta of 1.46. Dianthus Therapeutics, Inc. has a 1-year low of $13.36 and a 1-year high of $38.59.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The company had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analysts Set New Price Targets

DNTH has been the topic of a number of research reports. Robert W. Baird upped their target price on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday, September 9th. Stifel Nicolaus upped their target price on Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday. Raymond James Financial reiterated an “outperform” rating and issued a $63.00 target price (up previously from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. William Blair initiated coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an “outperform” rating on the stock. Finally, Guggenheim upped their target price on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Nine equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Buy” and an average target price of $61.57.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $27,000. US Bancorp DE grew its stake in shares of Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock valued at $29,000 after buying an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $59,000. GAMMA Investing LLC grew its stake in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after buying an additional 3,758 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after buying an additional 3,317 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.